EW
PGNX

Evoke Wealth’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Evoke Wealth’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,052
Closed -$5.32K – 1541
2019
Q3 		$5.32K Buy
+1,052
New +$5.25K ﹤0.01% 994

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Evoke Wealth's PGNX Position: Q4 2019 in Review

Evoke Wealth sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2019, closing a stake of 1,052 shares — an estimated $5.32K sold.

Evoke Wealth first reported a position in PGNX in Q3 2019 and held it in 1 quarter. The position peaked at $5.32K in Q3 2019. 128 funds tracked by Wall St. Rank hold PGNX as of Q4 2019.

  • Evoke Wealth reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2019 after selling out during the quarter.
  • Evoke Wealth sold 1,052 Progenics Pharmaceuticals Inc shares in Q4 2019, an estimated $5.32K.
  • Evoke Wealth first reported a position in Progenics Pharmaceuticals Inc in Q3 2019 and held it in 1 quarter.
  • Evoke Wealth's Progenics Pharmaceuticals Inc position peaked at $5.32K in Q3 2019.
  • 128 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2019.

Based on Evoke Wealth's 13F filing for Q4 2019, filed 7 Feb 2020.